Patent 7851181 was granted and assigned to Schering on December, 2010 by the United States Patent and Trademark Office.
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.